TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing...
Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international...
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing...
TORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing...
Rescheduling aligns with Avicanna’s established pharmaceutical and medical cannabis strategy Rescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives ...
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing...
An established forum for evidence-based clinical discussion, interdisciplinary dialogue, and patient considerations Event is expanded to two days, live and virtual on June 11-12, 2026, at the MaRS Discovery...
TORONTO, April 06, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing...
Achieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full year Advancements across business units, R&D, and clinical development to support scale and international...
This marks the first commercial export of organic certified flower for SMGH The export represents the 21 st market for SMGH and 24 th market for all Avicanna products TORONTO, March ...